Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial

T N Brooklyn, M G S Dunnill, A Shetty, J J Bowden, J D L Williams, C E M Griffiths, A Forbes, R Greenwood, C S Probert

Research output: Contribution to journalArticlepeer-review

523 Citations (Scopus)


Pyoderma gangrenosum (PG) is a chronic ulcerating skin condition that often occurs in association with inflammatory bowel disease. There have been a number of reports of PG responding to infliximab, a monoclonal antibody against tumour necrosis factor alpha.
Original languageEnglish
Pages (from-to)505-509
Number of pages5
Issue number4
Publication statusPublished - Apr 2006


  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal
  • Dermatologic Agents
  • Double-Blind Method
  • Female
  • Humans
  • Inflammatory Bowel Diseases
  • Male
  • Middle Aged
  • Pyoderma Gangrenosum
  • Quality of Life
  • Treatment Outcome

Cite this